CYMA News 7.0000 Cymabay Therapeutics (CYMA)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cymabay Therapeutics (CYMA) 7.0000 $CYMA

CymaBay reports launch of Phase 2b study of arhalofenate in gout patients
M2 - Thu Mar 27, 5:19AM CDT
Biopharmaceutical company CymaBay Therapeutics (OTC BB:CYMA) said on Wednesday that it has randomized the first patient under its Phase 2b clinical trial of arhalofenate for for the treatment of gout, a chronic, progressive rheumatic disease.

CymaBay Initiates Arhalofenate Phase 2b Gout Study
Marketwire - Wed Mar 26, 3:21PM CDT
CymaBay Therapeutics, Inc. (OTCQB: CYMA), a biopharmaceutical company developing therapies addressing unmet medical needs in metabolic disease, today announced that it has randomized the first patient in a Phase 2b clinical trial of arhalofenate (MBX-102). Arhalofenate is a dual acting product candidate for the treatment of gout that is targeted to lower serum uric acid (sUA) and reduce the incidence of flares.

CymaBay Therapeutics Appoints Pol Boudes M.D. to Position of Chief Medical Officer
Marketwire - Mon Mar 03, 8:02AM CST
CymaBay Therapeutics, Inc. (OTCQB: CYMA), a biopharmaceutical company developing breakthrough therapies addressing unmet medical needs in metabolic diseases, today announced that Dr. Pol Boudes has joined the company as Chief Medical Officer. Dr. Boudes brings extensive clinical development experience to CymaBay, including expertise in all phases of clinical trial design and execution.

CymaBay Therapeutics to Present at Cowen and Roth Investor Conferences
Marketwire - Tue Feb 25, 8:05AM CST
CymaBay Therapeutics, Inc. (OTCQB: CYMA) today announced that Harold Van Wart, President and Chief Executive Officer, will present an overview of the company at investment conferences hosted by Cowen and Company and ROTH Capital Partners.

Mixed Dyslipidemia - Pipeline Review, H2 2013 Research Report
M2 - Thu Feb 13, 2:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/85sdh6/mixed) has announced the addition of the "Mixed Dyslipidemia - Pipeline Review, H2 2013" report to their offering. 'Mixed Dyslipidemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mixed Dyslipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mixed Dyslipidemia. Scope - A snapshot of the global therapeutic scenario for Mixed Dyslipidemia. - A review of the Mixed Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mixed Dyslipidemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Mixed Dyslipidemia Overview Therapeutics Development Pipeline Products for Mixed Dyslipidemia - Overview Pipeline Products for Mixed Dyslipidemia - Comparative Analysis Mixed Dyslipidemia - Therapeutics under Development by Companies Mixed Dyslipidemia - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Mixed Dyslipidemia - Products under Development by Companies Mixed Dyslipidemia - Companies Involved in Therapeutics Development Mixed Dyslipidemia - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles evolocumab - Drug Profile Product Description Mechanism of Action R&D Progress bococizumab - Drug Profile Product Description Mechanism of Action R&D Progress INSUPR-001 DR - Drug Profile Product Description Mechanism of Action R&D Progress MBX-8025 - Drug Profile Product Description Mechanism of Action R&D Progress PRC-4016 - Drug Profile Product Description Mechanism of Action R&D Progress CAT-2003 - Drug Profile Product Description Mechanism of Action R&D Progress MAT-9001 - Drug Profile Product Description Mechanism of Action R&D Progress Mixed Dyslipidemia - Recent Pipeline Updates Mixed Dyslipidemia - Dormant Projects Mixed Dyslipidemia - Discontinued Products Mixed Dyslipidemia - Product Development Milestones Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Amgen Inc. Pfizer Inc. Pronova BioPharma ASA Intas Pharmaceuticals Ltd. Catabasis Pharmaceuticals, Inc. Matinas BioPharma, Inc. CymaBay Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/85sdh6/mixed About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CymaBay Therapeutics Announces Listing on OTCBB and OTC Link
Marketwire - Fri Jan 24, 8:00AM CST
CymaBay Therapeutics, Inc. (OTCBB: CYMA), a biopharmaceutical company developing breakthrough therapies addressing unmet medical needs, today announced that its common stock has been cleared for quotation on the OTC Bulletin Board (OTCBB) and the OTC Market Group's OTC Link quotation system under the ticker symbol "CYMA."
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 21

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

Nokia Leadership Stability Amidst Market Challenges

Updated Category News Views 146

Nokia Confirms Leadership Stability Nokia has recently made it clear that it isn't looking to replace its President and CEO, Pekka Lundmark, despite rumors to the contrary. The company shared this message with Reuters, stressing the board's complete support for Lundmark in his role. Company Assurance and Strategy The telecommunications giant explained that it continually...

Continue Reading
GoldMining Inc. Reports Share Disposition Update and Strategy

Updated Category News Views 121

GoldMining Inc. Reports Update on Share Disposition GoldMining Inc. (the "Company") has recently made a significant move by disposing of 3,500,000 common shares of NevGold Corp., marking a strategic adjustment in its investment portfolio. This block trade was executed over the facilities of the TSX Venture Exchange. Current Ownership Stakes Before this transaction,...

Continue Reading
Launching Hope: The Salvation Army's Red Kettle Campaign 2024

Updated Category News Views 119

Launching Hope: The Salvation Army's Red Kettle Campaign 2024 America's longest-running fundraising campaign, helping millions, is bringing communities together for the annual tradition. Red Kettle Campaign Kicks Off with Joy The Salvation Army is excited to announce the start of its 134th Red Kettle Campaign, a celebrated event symbolizing hope during the festive season....

Continue Reading
Yaletown Partners Secures $250 Million for Innovation Fund III

Updated Category News Views 263

Yaletown Partners Announces Major Fundraising Milestone Yaletown Partners, a prominent technology investment firm, is excited to share a significant development regarding its latest venture capital initiative, the Innovation Growth Fund III (IGF III). This round has reached an impressive first close of $100 million, marking it as the third and largest fund in Yaletown’s...

Continue Reading
Honda Issues Major Recall of 1.7 Million Vehicles Due to Safety Risks

Updated Category News Views 290

Honda's Vehicle Safety Recall Overview Honda (NYSE: HMC) has announced a significant recall affecting approximately 1.7 million vehicles in the United States. This decision comes in response to the potential risks associated with steering gearbox damage, an issue that has raised serious safety concerns among both the automotive manufacturer and the National Highway...

Continue Reading